 REDWOOD CITY, Calif., Oct. 27, 2020 GLOBE NEWSWIRE -- Allakos Inc. the Company Nasdaq: ALLK, a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and other conditions, 250 million of shares of its common stock in an underwritten public offering. In addition, Allakos expects to grant the underwriters a 30-day option to purchase up to 37.5 million of additional shares of the Companys common stock. All of the shares in the proposed offering will be sold by the Company. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. 